特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015
◆商品コード:GMDHC6354IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年2月28日
◆ページ数:91
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)の概要
・特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2015’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Overview 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Comparative Analysis 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Products under Development by Companies 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Companies Involved in Therapeutics Development 16
Anthera Pharmaceuticals‚ Inc. 16
Azano Pharmaceuticals Inc. 17
Boehringer Ingelheim GmbH 18
Bristol-Myers Squibb Company 19
Eisai Co., Ltd. 20
GlaxoSmithKline plc 21
HanAll Biopharma Co., Ltd. 22
Immunomedics, Inc. 23
Merck & Co., Inc. 24
Momenta Pharmaceuticals, Inc. 25
Pfizer Inc. 26
PhytoHealth Corporation 27
Rigel Pharmaceuticals, Inc. 28
SuppreMol GmbH 29
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
Antibody for Autoimmune Disorders and Inflammation – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
avatrombopag – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AZ-175 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BI-655064 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
blisibimod – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BMS-986004 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
eltrombopag olamine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fostamatinib disodium – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GL-2045 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GSK-2285921 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HL-161 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MK-8723 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PHN-013 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SM-101 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
veltuzumab – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Recent Pipeline Updates 67
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects 81
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products 82
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Product Development Milestones 83
Featured News & Press Releases 83
Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 83
Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 83
Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 83
Dec 09, 2013: Immunomedics Reports Promising Activity With Veltuzumab In Relapsed Immune Thrombocytopenia 84
Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 85
Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 85
Jun 12, 2013: GSK’s Revolade Receives Positive Recommendation From NICE For Treatment Of Idiopathic Thrombocytopenic Purpura 86
Mar 20, 2013: GSK’s Eltrombopag Receives NICE Recommendation For Treatment Of Chronic Immune Thrombocytopenic Purpura 86
Dec 18, 2012: NICE Recommends GlaxoSmithKline’s Eltrombopag For Treatment Of Chronic Immune Thrombocytopenic Purpura 87
Dec 11, 2012: Immunomedics Provides Clinical Updates On Subcutaneous Injections Of Veltuzumab In Autoimmune Disease And Cancer 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

[List of Tables]
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2015 9
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Azano Pharmaceuticals Inc., H1 2015 17
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H1 2015 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H1 2015 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Eisai Co., Ltd., H1 2015 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GlaxoSmithKline plc, H1 2015 21
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 22
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H1 2015 23
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H1 2015 24
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 25
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H1 2015 26
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H1 2015 27
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 28
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by SuppreMol GmbH, H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics - Recent Pipeline Updates, H1 2015 67
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H1 2015 81
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H1 2015 82

[List of Figures]
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2015 9
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Top 10 Targets, H1 2015 31
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36
Number of Products by Top 10 Molecule Types, H1 2015 37
Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

【掲載企業】

Anthera Pharmaceuticals‚ Inc.
Azano Pharmaceuticals Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai Co., Ltd.
GlaxoSmithKline plc
HanAll Biopharma Co., Ltd.
Immunomedics, Inc.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Pfizer Inc.
PhytoHealth Corporation
Rigel Pharmaceuticals, Inc.
SuppreMol GmbH

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)(Idiopathic Thrombocytopenic Purpura):治療薬開発パイプライン動向(2015年上半期版)(Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆